Researchers developed OVX836, a specialized recombinant protein vaccine designed to provide broad protection against diverse influenza A subtypes. Unlike traditional shots that target frequently mutating surface proteins, this candidate utilizes a highly stable, heptameric nucleoprotein to trigger robust cellular immune responses. Laboratory tests on mice demonstrated that the vaccine successfully induces CD4+ and CD8+ T-cell activity both systemically and within lung tissue. These defenses resulted in significant viral load reductions and high survival rates when subjects were exposed to different flu strains. Furthermore, the study suggests that combining OVX836 with standard inactivated vaccines enhances overa ...